As the first anti-HER-2 targeted therapy drug, trastuzumab has been clinically used for more than 10 years and has established its status as a first-line anti-HER-2 standard therapy, which can significantly improve the prognosis of patients with HER-2-positive breast cancer [5, 6] But the problems of drug resistance and toxicity in the treatment process have always plagued clinicians, and small molecule targeted drugs including imported lapatinib, neratinib, and domestically produced pyrotinib have appeared one after another. This evidence concerns the gene ERBB2 and breast cancer.